Inventory of 8 global biotechnology IPOs in the first half of 2019, with 3 seats in HKEx

Since the reform of the Hong Kong Stock Exchange last year, a number of biotech companies have been encouraged to go public in Hong Kong, opening the door to Hong Kong IPO for companies with different rights and eligible unprofitable biotech companies This paper reviews eight biotechnology companies listed on NASDAQ and HKEx as of the end of June this year Three of them are listed on the Hong Kong stock exchange Let's take a look at the 8 global biotechnology IPOs 1 Hansen Pharmaceutical (also known as hausen pharmaceutical) was officially listed on the Hong Kong Stock Exchange in June, raising about $980 million Hansen pharmaceutical was founded in 1995 It is committed to six fields: central nervous system, anti-tumor, anti infection, diabetes, digestive tract and cardiovascular In 2002, Hansen pharmaceutical began to develop a new class 1.1 drug Class 1.1 new drugs under research include: new type 2 diabetes drug (pegylated losenapeptide), flumatine mesylate, new hepatitis B drug hs-10234 and the third generation molecular targeted drug hs-10296 of non-small cell lung cancer (NSCLC) At present, the company has nearly 100 products under development, six of which are class 1.1 molecular entity innovative drugs that have entered phase 2 clinical trials or later stage It is worth mentioning that Hansen pharmaceutical has launched four new drugs between December last year and may this year One of them is polyethylene glycol loseptide injection (trade name: Flemish), a new class 1 drug approved by China National Drug Administration through the priority review and approval process in May this year, which is used to improve the blood glucose control of type 2 diabetes patients in adults According to the announcement, this is also the first long-term hypoglycemic drug in China, which only needs to be administered once a week to achieve long-term treatment 2 In June, bridgebio Pharma, a company dedicated to developing innovative therapies for genetic diseases, officially landed on NASDAQ and raised 348 million US dollars through IPO Bridgebio's main research and development areas are rare diseases caused by single gene defects and cancer with clear genetic drivers The company has a unique organizational structure, with multiple R & D projects, each of which is carried out by a semi autonomous branch company They can share resources with other branches and parent companies This framework enables bridgebio to flexibly allocate resources and improve operational efficiency according to the progress and requirements of the project At present, there are 16 R & D projects in the company's R & D pipeline, three of which are in phase 3 clinical trials The 3-stage clinical in development therapies for the treatment of hereditary rare diseases are: bbp-265, a transthyroxin protein stabilizer, for the treatment of attr; bbp-009, a hedgehog (Hh) inhibitor, for the treatment of Gorlin syndrome; and bbp-870, for the treatment of mocd type A deficiency 3 Adaptive biotechnology, which is committed to high-throughput gene sequencing using computer infrastructure, landed on NASDAQ in June and raised $317 million through IPO Adaptive was founded in 2009, and its immune sequencing platform has gradually entered laboratories around the world, promoting breakthrough research on cancer and other immune-mediated diseases At the same time, the company also transformed its immune sequencing results into clinical diagnosis and treatment means to improve the level of patient care In addition, the T-cell receptor discovery platform developed by adaptive can identify and analyze millions of T-cell and B-cell receptors from a single sample with high precision, helping scientists to accurately analyze T-cell receptors In early 2018, adaptive worked with Microsoft to develop a blood test that can diagnose multiple diseases in one test In January 2019, adaptive reached an agreement with Genentech, a subsidiary of Roche, to develop, produce and commercialize new antigen-directed T-cell therapy for individualized treatment of multiple cancers 4 In February, cstone pharmaceuticals was listed on the Hong Kong stock exchange, raising $310 million through an IPO Only three years after its establishment, cornerstone pharmaceutical, with its core competitiveness in clinical development, strong drug pipeline and excellent team, has been recognized by well-known investors in two rounds of financing so far, and has broken the financing record of China's biomedical industry at that time At present, cornerstone pharmaceutical has a strong product pipeline composed of 14 tumor candidate drugs, including 4 late candidate drugs in or near critical trials In July this year, the company's avapritinib delivered its first Chinese trial, and the product is currently undergoing global phase 3 clinical research The purpose of this study was to evaluate the efficacy and safety of avapritinib in the treatment of advanced gastrointestinal stromal tumor (GIST) compared with current standard Avapritinib is an oral, powerful and highly selective kit and PDGFRA inhibitor developed by cornerstone pharmaceutical partner blueprint medicines 5 In February, gossamer bio was listed on NASDAQ and raised US $290 million through IPO Founded in 2017, the company's main research direction is immunology At present, there are five research and development projects in the drug research and development pipeline, three of which have entered the clinical trial stage The company's leading candidate drug, GB001, is a DP2 antagonist for eosinophilic asthma, a chronic lung disease that is difficult to control At present, the drug is in phase 2B clinical research Another HIF-1 α stabilizer from the company is currently used in phase 1 clinical trials to treat inflammatory bowel disease 6 In April, turning point therapeutics officially landed on NASDAQ and raised US $192 million The company said it will use IPO funds to promote its main candidate drug, repotrectinib, into phase 2 clinical, and promote the other two candidate drugs into early clinical Repotrectinib is a ros1 / Trks / ALK inhibitor, which has the potential to treat ros1 positive non-small cell lung cancer and ntrk positive solid tumor The new drug has obtained the orphan drug qualification issued by FDA in 2017 Turning point therapeutics was founded in October 2013, focusing on the research and development of precise anti-cancer therapy The company's scientific founder, Dr J Jean Cui, is the main inventor of two precision antitumor drugs, cripotinib and loratinib The former has been approved by FDA in 2011 and is used to treat non-small cell lung cancer with ALK mutation The latter was approved by FDA in November 2018 for the treatment of ALK positive non-small cell lung cancer 7 Alector, which focuses on the treatment of degenerative brain diseases (such as Alzheimer's disease), officially landed on NASDAQ in February with an IPO of $170 million Alector focuses on microglia, an immune cell that nourishes neurons, eating cell fragments and pathological proteins Alector believes that the root cause of neurodegenerative diseases is the problem of immune cells in the brain, which deteriorate with age, thus reducing their ability to play a beneficial and protective role This viewpoint will challenge some long-standing theories that amyloid β and tau, the protein of Alzheimer's disease, α - synuclein of Parkinson's disease, TDP-43 in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are the root causes of the disease At present, the company has two products in the clinical stage: al001 product has been given to 42 patients with temporal lobe dementia (FTD), the company said, no serious adverse reactions or problems that need to limit the dosage of the drug have been found; the other main drug is al002, which is used for the experimental treatment of Alzheimer's disease, and the phase 1 dose incremental study has been carried out in healthy patients 8 In March, cansino biology was officially listed on the Hong Kong stock exchange, raising US $160 million Conchino was founded in 2009 Its core business is the R & D, production and commercialization of innovative vaccines The company has four innovative vaccine platform technologies, including adenovirus vector vaccine technology, combination technology, protein structure design and recombination technology, and preparation technology At present, ConocoPhillips has 15 new vaccines under development, covering 12 disease areas, one of which is the Ebola vaccine Ad5 EBOV, which was approved for marketing in October 2017; two vaccines under development are close to commercialization; mcv2, a bivalent vaccine, has submitted new drug registration application in early 2019; a new bivalent vaccine, a bivalent vaccine, plans to submit new drug registration application within this year In addition, six new vaccines under development, including DPT vaccine combination, pneumococcal vaccine and tuberculosis enhanced vaccine, are in clinical stage 1-3.